Quick Answer
HAEMONETICS CORP reported Total Revenue of $903.92 million for fiscal year 2018.
HAEMONETICS CORP — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | $167.68M +42.6% |
$117.56M +1.9% |
$115.40M +166.1% |
$43.38M -45.4% |
$79.47M +3.8% |
$76.53M +39.1% |
| Diluted EPS | $3.31 +44.5% |
$2.29 +2.2% |
$2.24 +166.7% |
$0.84 -45.8% |
$1.55 +4.7% |
$1.48 +42.3% |
| Total Assets | $2.45B +11.6% |
$2.20B +13.5% |
$1.93B +4.0% |
$1.86B +2.2% |
$1.82B +43.6% |
$1.27B -0.6% |
| Cash and Equivalents | $306.76M +71.6% |
$178.80M -37.1% |
$284.47M +9.6% |
$259.50M +34.9% |
$192.31M +40.1% |
$137.31M -18.9% |
| Long-Term Debt | $921.23M +15.5% |
$797.56M +5.8% |
$754.10M +34.8% |
$559.44M -19.0% |
$690.59M +126.0% |
$305.51M -5.3% |
| Stockholders Equity | $820.84M -14.5% |
$959.96M +17.4% |
$818.00M +9.2% |
$749.42M +2.4% |
$731.67M +24.6% |
$587.11M -12.1% |
| R&D Expense | $62.72M +15.2% |
$54.44M +8.6% |
$50.13M +7.1% |
$46.80M +42.4% |
$32.86M +6.4% |
$30.88M -13.5% |
| Operating Income | $221.82M +34.5% |
$164.88M +5.7% |
$156.03M +93.2% |
$80.75M -10.0% |
$89.75M -13.2% |
$103.35M +23.7% |
| Gross Profit | $748.96M +8.3% |
$691.55M +12.4% |
$615.10M +21.7% |
$505.50M +27.1% |
$397.84M -17.9% |
$484.51M +16.0% |
| Shares Outstanding | 48.22M -5.1% |
50.79M +0.7% |
50.45M -1.3% |
51.12M +0.5% |
50.87M +1.1% |
50.32M -1.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $338.97M | -2.7% | +3.6% |
| Revenue (ASC 606) | December 31, 2025 | $338.97M | -2.7% | +3.6% |
| Net Income | December 31, 2025 | $44.74M | +19.3% | +15.7% |
| Diluted EPS | December 31, 2025 | $0.95 | +28.4% | +17.3% |
| Total Assets | December 31, 2025 | $2.49B | -1.6% | +2.0% |
| Cash and Equivalents | December 31, 2025 | $363.37M | +13.3% | +22.6% |
| Long-Term Debt | December 31, 2025 | $919.99M | -24.6% | -0.0% |
| Stockholders Equity | December 31, 2025 | $911.45M | +0.5% | +7.3% |
| R&D Expense | December 31, 2025 | $14.19M | -10.4% | -4.6% |
| Operating Income | December 31, 2025 | $67.40M | +14.2% | +15.2% |
| Gross Profit | December 31, 2025 | $202.39M | +4.6% | +3.9% |
| Shares Outstanding | December 31, 2025 | 46.83M | -6.8% | +0.2% |
- HAEMONETICS CORP reported Total Revenue of $903.92 million for fiscal year 2018.
- HAEMONETICS CORP showed an increase of +2.0% in Total Revenue compared to the prior fiscal year.
- HAEMONETICS CORP reported Net Income of $167.68 million for fiscal year 2025.
- HAEMONETICS CORP showed an increase of +42.6% in Net Income compared to the prior fiscal year.
- HAEMONETICS CORP reported Diluted EPS of $3.31 per share for fiscal year 2025.
- HAEMONETICS CORP showed an increase of +44.5% in Diluted EPS compared to the prior fiscal year.
- HAEMONETICS CORP reported Total Assets of $2.45 billion for fiscal year 2025.
- HAEMONETICS CORP showed an increase of +11.6% in Total Assets compared to the prior fiscal year.
- HAEMONETICS CORP reported Cash and Equivalents of $306.76 million for fiscal year 2025.
- HAEMONETICS CORP showed an increase of +71.6% in Cash and Equivalents compared to the prior fiscal year.
- HAEMONETICS CORP reported Long-Term Debt of $921.23 million for fiscal year 2025.
- HAEMONETICS CORP showed an increase of +15.5% in Long-Term Debt compared to the prior fiscal year.
- HAEMONETICS CORP reported Stockholders Equity of $820.84 million for fiscal year 2025.
- HAEMONETICS CORP showed a decrease of -14.5% in Stockholders Equity compared to the prior fiscal year.
- HAEMONETICS CORP reported R&D Expense of $62.72 million for fiscal year 2025.
- HAEMONETICS CORP showed an increase of +15.2% in R&D Expense compared to the prior fiscal year.
- HAEMONETICS CORP reported Operating Income of $221.82 million for fiscal year 2025.
- HAEMONETICS CORP showed an increase of +34.5% in Operating Income compared to the prior fiscal year.
- HAEMONETICS CORP reported Gross Profit of $748.96 million for fiscal year 2025.
- HAEMONETICS CORP showed an increase of +8.3% in Gross Profit compared to the prior fiscal year.
- HAEMONETICS CORP reported Shares Outstanding of 48.22 million shares for fiscal year 2025.
- HAEMONETICS CORP showed a decrease of -5.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: